These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
744 related articles for article (PubMed ID: 29164421)
1. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421 [TBL] [Abstract][Full Text] [Related]
2. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175 [TBL] [Abstract][Full Text] [Related]
3. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902 [TBL] [Abstract][Full Text] [Related]
4. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303 [TBL] [Abstract][Full Text] [Related]
5. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092 [TBL] [Abstract][Full Text] [Related]
6. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Hortobagyi GN Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505 [TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329 [TBL] [Abstract][Full Text] [Related]
8. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Janni W; Alba E; Bachelot T; Diab S; Gil-Gil M; Beck TJ; Ryvo L; Lopez R; Tsai M; Esteva FJ; Auñón PZ; Kral Z; Ward P; Richards P; Pluard TJ; Sutradhar S; Miller M; Campone M Breast Cancer Res Treat; 2018 Jun; 169(3):469-479. PubMed ID: 29404806 [TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Verma S; O'Shaughnessy J; Burris HA; Campone M; Alba E; Chandiwana D; Dalal AA; Sutradhar S; Monaco M; Janni W Breast Cancer Res Treat; 2018 Aug; 170(3):535-545. PubMed ID: 29654415 [TBL] [Abstract][Full Text] [Related]
10. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922 [TBL] [Abstract][Full Text] [Related]
11. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171 [TBL] [Abstract][Full Text] [Related]
13. Everolimus Plus Letrozole for Treatment of Patients With HR Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108 [TBL] [Abstract][Full Text] [Related]
14. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. Borstnar S; Palacova M; Łacko A; Timcheva C; Gal-Yam EN; Papazisis K; Beniak J; Kudela P; Rubovszky G Radiol Oncol; 2022 May; 56(2):238-247. PubMed ID: 35575587 [TBL] [Abstract][Full Text] [Related]
15. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010 [TBL] [Abstract][Full Text] [Related]
16. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Hart L; Campone M; Petrakova K; Winer EP; Janni W; Conte P; Cameron DA; André F; Arteaga CL; Zarate JP; Chakravartty A; Taran T; Le Gac F; Serra P; O'Shaughnessy J N Engl J Med; 2022 Mar; 386(10):942-950. PubMed ID: 35263519 [TBL] [Abstract][Full Text] [Related]
17. MONALEESA clinical program: a review of ribociclib use in different clinical settings. Yardley DA Future Oncol; 2019 Aug; 15(23):2673-2686. PubMed ID: 31305131 [TBL] [Abstract][Full Text] [Related]
18. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697 [TBL] [Abstract][Full Text] [Related]
19. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253 [TBL] [Abstract][Full Text] [Related]
20. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]